{"entity":{"edinet_code":"E02780","sec_code":"9987","name_ja":"株式会社スズケン","name_en":"SUZUKEN CO.,LTD.","industry":"卸売業","industry_en":"Wholesale Trade"},"names_note":"English company names are as filed: each company's own annual report states its English name on the cover page. For a company that files no annual report, EDINET's filer registry is used instead. The as-filed Japanese name is always returned alongside.","filing":{"doc_id":"S100YFRU","filer_name":"株式会社スズケン","filer_name_en":"SUZUKEN CO.,LTD.","period_end":"2026-03-31","filed_date":"2026-06-22","sha256":"dceff2a61c66293b18d5606dd77b275be200a04b2e19de2bea7856b2f46985fb","status":"clean"},"basis":{"measurement":"carrying_amount","entity_scope":"parent_only","share_scope":"both","trust_included":"unknown","as_of":"2026-03-31","period_type":"annual","labels":{"measurement":"Balance-sheet carrying amount. Under Japanese GAAP listed equities are carried at market with the valuation difference in other comprehensive income, so carrying amount and acquisition cost diverge enormously on positions bought decades ago.","entity_scope":"The reporting company itself (提出会社) — the holding company, excluding the group holders it names separately.","share_scope":"Listed and unlisted shares together.","trust_included":"The filing does not state whether retirement-benefit-trust shares are included. Never guessed — shares contributed to such a trust leave the holder's balance sheet while the settlor normally keeps the right to instruct the vote.","period_type":"From an annual securities report (有価証券報告書). The policy shareholding table appears only in the annual report."},"not_comparable":"Figures are balance-sheet CARRYING AMOUNT at fiscal year end, from the annual securities report. They are NOT comparable with the acquisition-cost or book-value-reduction figures quoted in press coverage and IR presentations, and NOT comparable with interim (half-year) figures, which this product does not hold. Always state the basis with the number, and use check_claim before setting one of our figures against a published one."},"basis_note":"The basis every yen figure on this response is on. entity_scope is read from the filing's own disclosing entities, not assumed: scale_entities and flows each carry their own entity_scope and share_scope, and a figure quoted for one entity is not the group figure.","holdings":[{"holder_table":"reporting","held_name_raw":"大塚ホールディングス㈱","held_name_en":"Otsuka Holdings Co., Ltd.","held_sec_code":"4578","match_status":"matched","shares":3292000,"book_value_yen":36244000000,"prior_shares":3292000,"prior_book_value_yen":25522000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております","reciprocal":"無(注)２","pct_outstanding":0.6233297043186506,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":8.712248685134083,"pct_of_holder_assets":3.1359288991024137,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"小野薬品工業㈱","held_name_en":"ONO　PHARMACEUTICAL　CO.,　LTD.","held_sec_code":"4528","match_status":"matched","shares":1243000,"book_value_yen":3120000000,"prior_shares":1243000,"prior_book_value_yen":1991000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"有","pct_outstanding":0.25987564020248977,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.7499783660086728,"pct_of_holder_assets":0.2699508377993469,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"参天製薬㈱","held_name_en":"SANTEN PHARMACEUTICAL CO., LTD.","held_sec_code":"4536","match_status":"matched","shares":1338000,"book_value_yen":2388000000,"prior_shares":1338000,"prior_book_value_yen":1897000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"無","pct_outstanding":0.4159060709274526,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5740219032143303,"pct_of_holder_assets":0.20661621816180784,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"三菱ケミカルグループ㈱","held_name_en":"Mitsubishi Chemical Group Corporation","held_sec_code":"4188","match_status":"matched","shares":857000,"book_value_yen":770000000,"prior_shares":857000,"prior_book_value_yen":631000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"無","pct_outstanding":0.0630130699981894,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.18509081468803784,"pct_of_holder_assets":0.06662248240560806,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ツムラ","held_name_en":"TSUMURA & CO.","held_sec_code":"4540","match_status":"matched","shares":180705,"book_value_yen":676000000,"prior_shares":180705,"prior_book_value_yen":779000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"有","pct_outstanding":0.24001876955942777,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.16249531263521244,"pct_of_holder_assets":0.0584893481898585,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"サスメド㈱","held_name_en":"SUSMED,Inc.","held_sec_code":"4263","match_status":"matched","shares":700000,"book_value_yen":674000000,"prior_shares":700000,"prior_book_value_yen":413000000,"purpose_ja":"保有目的 　共同で取り組んでいる事業を進める中で、同社と　の良好な関係の維持、強化業務提携等の概要　当社グループの治験薬物流やキュービックス®　ＣＴとサスメドの臨床研究・治験管理システム　の相互連携による新たな臨床研究・治験サービス　の開発、展開等定量的な保有効果 　両社の経営資源を有効活用することによる新たな　付加価値の創出 ","reciprocal":"無","pct_outstanding":4.151370841957312,"pct_unavailable":null,"pct_basis_period_end":"2026-06-30","pct_share_classes":1,"pct_of_holder_equity":0.16201455727238637,"pct_of_holder_assets":0.05831630278101277,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱Welby","held_name_en":"Welby Inc.","held_sec_code":"4438","match_status":"matched","shares":1657900,"book_value_yen":532000000,"prior_shares":null,"prior_book_value_yen":null,"purpose_ja":"保有目的　共同で取り組んでいる事業を進める中で、同社と　の良好な関係の維持、強化定量的な保有効果　両社の経営資源を有効活用することによる新た　な付加価値の創出株式数が増加した理由　関係会社株式からの振替","reciprocal":"無","pct_outstanding":20.03363630497529,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.12788092651173524,"pct_of_holder_assets":0.04603007875296557,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"日本化薬㈱","held_name_en":"NIPPON KAYAKU CO.,LTD.","held_sec_code":"4272","match_status":"matched","shares":300000,"book_value_yen":526000000,"prior_shares":300000,"prior_book_value_yen":423000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"有","pct_outstanding":0.20205435396824648,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.12643866042325702,"pct_of_holder_assets":0.04551094252642836,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"キッセイ薬品工業㈱","held_name_en":"KISSEI PHARMACEUTICAL CO., LTD.","held_sec_code":"4547","match_status":"matched","shares":95990,"book_value_yen":446000000,"prior_shares":344560,"prior_book_value_yen":1324000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております","reciprocal":"無","pct_outstanding":0.2315685688669219,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.10720844591021413,"pct_of_holder_assets":0.03858912617259895,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"明治ホールディングス㈱","held_name_en":"Meiji Holdings Co.,Ltd.","held_sec_code":"2269","match_status":"matched","shares":112800,"book_value_yen":435000000,"prior_shares":112800,"prior_book_value_yen":366000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております","reciprocal":"無(注)２","pct_outstanding":0.041607955677198986,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.10456429141467073,"pct_of_holder_assets":0.037637376423947405,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"杏林製薬㈱","held_name_en":"KYORIN Pharmaceutical Co., Ltd.","held_sec_code":"4569","match_status":"matched","shares":201000,"book_value_yen":330000000,"prior_shares":201000,"prior_book_value_yen":301000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"有","pct_outstanding":0.34592225894601,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.07932463486630194,"pct_of_holder_assets":0.02855249245954631,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"持田製薬㈱","held_name_en":"Mochida Pharmaceutical Co.,Ltd.","held_sec_code":"4534","match_status":"matched","shares":81200,"book_value_yen":280000000,"prior_shares":81200,"prior_book_value_yen":258000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"有","pct_outstanding":0.22905694547485592,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.06730575079565013,"pct_of_holder_assets":0.02422635723840293,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ゼリア新薬工業㈱ ","held_name_en":"ZERIA PHARMACEUTICAL CO., LTD.","held_sec_code":"4559","match_status":"matched","shares":104500,"book_value_yen":229000000,"prior_shares":104500,"prior_book_value_yen":235000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"有","pct_outstanding":0.23707170840678965,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.05504648904358528,"pct_of_holder_assets":0.01981369931283668,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"住友ファーマ㈱","held_name_en":"Sumitomo Pharma Co., Ltd.","held_sec_code":"4506","match_status":"matched","shares":93000,"book_value_yen":193000000,"prior_shares":93000,"prior_book_value_yen":67000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"無","pct_outstanding":0.023408648958146226,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.04639289251271598,"pct_of_holder_assets":0.016698881953613447,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"科研製薬㈱","held_name_en":"KAKEN PHARMACEUTICAL CO., LTD.","held_sec_code":"4521","match_status":"matched","shares":46500,"book_value_yen":192000000,"prior_shares":46500,"prior_book_value_yen":208000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております","reciprocal":"有","pct_outstanding":0.1221497408718024,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.04615251483130294,"pct_of_holder_assets":0.01661235924919058,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱マツキヨココカラ＆カンパニー","held_name_en":"MatsukiyoCocokara&Co.","held_sec_code":"3088","match_status":"matched","shares":75300,"book_value_yen":190000000,"prior_shares":74279,"prior_book_value_yen":173000000,"purpose_ja":"保有目的 　取引拡大を目的とし、同社との良好な取引関係の　維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております 株式数が増加した理由　取引先持株会への拠出による取得  ","reciprocal":"有","pct_outstanding":0.018891676756235376,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.04567175946847687,"pct_of_holder_assets":0.016439313840344846,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"わかもと製薬㈱","held_name_en":"WAKAMOTO PHARMACEUTICAL CO.,LTD.","held_sec_code":"4512","match_status":"matched","shares":385000,"book_value_yen":135000000,"prior_shares":385000,"prior_book_value_yen":122000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております","reciprocal":"有","pct_outstanding":1.1093206707500232,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.032450986990759885,"pct_of_holder_assets":0.011680565097087127,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"堺化学工業㈱","held_name_en":"SAKAI CHEMICAL INDUSTRY CO., LTD.","held_sec_code":"4078","match_status":"matched","shares":36180,"book_value_yen":125000000,"prior_shares":36180,"prior_book_value_yen":98000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております","reciprocal":"無(注)２","pct_outstanding":0.23629761220544437,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.03004721017662952,"pct_of_holder_assets":0.010815338052858451,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"住友化学㈱","held_name_en":"SUMITOMO CHEMICAL COMPANY, LIMITED","held_sec_code":"4005","match_status":"matched","shares":247000,"book_value_yen":123000000,"prior_shares":247000,"prior_book_value_yen":89000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"無","pct_outstanding":0.01496627559746116,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.029566454813803447,"pct_of_holder_assets":0.010642292644012716,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱セブン＆アイ・ホールディングス","held_name_en":"Seven & i Holdings Co., Ltd.","held_sec_code":"3382","match_status":"matched","shares":51300,"book_value_yen":108000000,"prior_shares":51300,"prior_book_value_yen":110000000,"purpose_ja":"保有目的　取引拡大を目的とし、同社との良好な取引関係の　維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております","reciprocal":"無","pct_outstanding":0.002216200465231973,"pct_unavailable":null,"pct_basis_period_end":"2026-02-28","pct_share_classes":1,"pct_of_holder_equity":0.025960789592607905,"pct_of_holder_assets":0.009344452077669702,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱サンドラッグ","held_name_en":"SUNDRUG CO.,LTD.","held_sec_code":"9989","match_status":"matched","shares":22014,"book_value_yen":86000000,"prior_shares":21503,"prior_book_value_yen":90000000,"purpose_ja":"保有目的　取引拡大を目的とし、同社との良好な取引関係の　維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております株式数が増加した理由 　取引先持株会への拠出による取得 ","reciprocal":"無","pct_outstanding":0.018818121445765137,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.02067248060152111,"pct_of_holder_assets":0.007440952580366614,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"扶桑薬品工業㈱","held_name_en":"Fuso Pharmaceutical Industries, Ltd.","held_sec_code":"4538","match_status":"matched","shares":36500,"book_value_yen":86000000,"prior_shares":36500,"prior_book_value_yen":89000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"無","pct_outstanding":0.42754720618985276,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.02067248060152111,"pct_of_holder_assets":0.007440952580366614,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ステラファーマ㈱","held_name_en":"STELLA PHARMA CORPORATION","held_sec_code":"4888","match_status":"matched","shares":88700,"book_value_yen":67000000,"prior_shares":88700,"prior_book_value_yen":33000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております","reciprocal":"無","pct_outstanding":0.26072898295120517,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.016105304654673424,"pct_of_holder_assets":0.00579702119633213,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱アインホールディングス","held_name_en":"AIN HOLDINGS INC.","held_sec_code":"9627","match_status":"matched","shares":10000,"book_value_yen":56000000,"prior_shares":10000,"prior_book_value_yen":50000000,"purpose_ja":"保有目的　取引拡大を目的とし、同社との良好な取引関係の　維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"無","pct_outstanding":0.02830062234200555,"pct_unavailable":null,"pct_basis_period_end":"2026-04-30","pct_share_classes":1,"pct_of_holder_equity":0.013461150159130025,"pct_of_holder_assets":0.004845271447680586,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"あすか製薬ホールディングス㈱","held_name_en":"ASKA Pharmaceutical Holdings Co., Ltd.","held_sec_code":"4886","match_status":"matched","shares":21000,"book_value_yen":49000000,"prior_shares":21000,"prior_book_value_yen":48000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"無(注)２","pct_outstanding":0.07394835144299115,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.011778506389238773,"pct_of_holder_assets":0.004239612516720513,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"帝人㈱","held_name_en":"TEIJIN LIMITED","held_sec_code":"3401","match_status":"matched","shares":30000,"book_value_yen":48000000,"prior_shares":30000,"prior_book_value_yen":39000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"無(注)２","pct_outstanding":0.01555081717548569,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.011538128707825735,"pct_of_holder_assets":0.004153089812297645,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱不二越","held_name_en":"NACHI-FUJIKOSHI CORP.","held_sec_code":"6474","match_status":"matched","shares":9049,"book_value_yen":40000000,"prior_shares":8723,"prior_book_value_yen":29000000,"purpose_ja":"保有目的　取引拡大を目的とし、同社との良好な取引関係の　維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております株式数が増加した理由  取引先持株会への拠出による取得","reciprocal":"無","pct_outstanding":0.041116599433218874,"pct_unavailable":null,"pct_basis_period_end":"2025-11-30","pct_share_classes":1,"pct_of_holder_equity":0.009615107256521446,"pct_of_holder_assets":0.003460908176914704,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ロート製薬㈱","held_name_en":"ROHTO PHARMACEUTICAL CO.,LTD.","held_sec_code":"4527","match_status":"matched","shares":4000,"book_value_yen":9000000,"prior_shares":4000,"prior_book_value_yen":8000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"有","pct_outstanding":0.001770191053622583,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0021633991327173253,"pct_of_holder_assets":0.0007787043398058085,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"日本ケミファ㈱","held_name_en":"NIPPON CHEMIPHAR CO., LTD.","held_sec_code":"4539","match_status":"matched","shares":1100,"book_value_yen":1000000,"prior_shares":1100,"prior_book_value_yen":1000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"無","pct_outstanding":0.03012774162448783,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.00024037768141303616,"pct_of_holder_assets":8.652270442286761e-05,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"アルフレッサ　　ホールディングス㈱","held_name_en":"Alfresa Holdings Corporation","held_sec_code":"2784","match_status":"matched","shares":100,"book_value_yen":0,"prior_shares":100,"prior_book_value_yen":0,"purpose_ja":"保有目的　同社との良好な取引関係の維持、強化定量的な保有効果　保有先企業との関係を考慮し総合的に保有の合理　性を検証しております ","reciprocal":"無(注)２","pct_outstanding":5.488404921342925e-05,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0,"pct_of_holder_assets":0.0,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"エーザイ㈱","held_name_en":"Eisai Co., Ltd.","held_sec_code":"4523","match_status":"matched","shares":100,"book_value_yen":0,"prior_shares":100,"prior_book_value_yen":0,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当金及び取引高を総合的に勘案し検証しております","reciprocal":"有","pct_outstanding":3.544666981355112e-05,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0,"pct_of_holder_assets":0.0,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"塩野義製薬㈱","held_name_en":"Shionogi & Co., Ltd.","held_sec_code":"4507","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":3783000,"prior_book_value_yen":8496000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"久光製薬㈱","held_name_en":"HISAMITSU PHARMACEUTICAL CO.,INC.","held_sec_code":null,"match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":9300,"prior_book_value_yen":37000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-02-28","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ウエルシアホールディングス㈱(注)３","held_name_en":"WELCIA HOLDINGS CO., LTD.","held_sec_code":null,"match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":60000,"prior_book_value_yen":129000000,"purpose_ja":"保有目的　取引拡大を目的とし、同社との良好な取引関係の　維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-02-28","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ツルハホールディングス","held_name_en":"TSURUHA HOLDINGS INC.","held_sec_code":"3391","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":16000,"prior_book_value_yen":149000000,"purpose_ja":"保有目的　取引拡大を目的とし、同社との良好な取引関係の　維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-02-28","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":["share exchange"],"note_refs":["3"],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"テルモ㈱","held_name_en":"TERUMO CORPORATION","held_sec_code":"4543","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":1238100,"prior_book_value_yen":3462000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ケアネット","held_name_en":"CareNet,Inc.","held_sec_code":null,"match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":50400,"prior_book_value_yen":34000000,"purpose_ja":"保有目的　同社との良好な取引関係の維持、強化定量的な保有効果　保有先企業との関係を考慮し総合的に保有の合理　性を検証しております ","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2024-12-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false}],"holders":[{"holder_name":"田辺三菱製薬株式会社","holder_name_en":"Mitsubishi Tanabe Pharma Corporation","holder_sec_code":"4508","doc_id":"S100G3TB","period_end":"2019-03-31","holder_table":"reporting","shares":1548191,"book_value_yen":9923000000,"prior_shares":1548191,"prior_book_value_yen":6804000000,"purpose_ja":null,"reciprocal":"有","pct_outstanding":1.696233455670217,"pct_unavailable":null,"pct_basis_period_end":"2019-03-31","pct_share_classes":1,"pct_of_holder_equity":1.1054986385978671,"pct_of_holder_assets":0.9394236030771969,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":897604000000,"holder_total_assets_yen":1056286000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"小野薬品工業株式会社","holder_name_en":"ONO　PHARMACEUTICAL　CO.,　LTD.","holder_sec_code":"4528","doc_id":"S100YOIE","period_end":"2026-03-31","holder_table":"reporting","shares":432058,"book_value_yen":2564000000,"prior_shares":432058,"prior_book_value_yen":2134000000,"purpose_ja":"取引先(特約店)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.6387808823880764,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3013892823432194,"pct_of_holder_assets":0.23171850359010046,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"大塚ホールディングス株式会社","holder_name_en":"Otsuka Holdings Co., Ltd.","holder_sec_code":"4578","doc_id":"S100XUA7","period_end":"2025-12-31","holder_table":"largest","shares":228860,"book_value_yen":1403000000,"prior_shares":228860,"prior_book_value_yen":1084000000,"purpose_ja":"医薬品販売等に係る事業上の関係の維持・強化を目的として保有しています。これにより、大塚製薬㈱の事業基盤の安定化に資する協力関係の構築を図っています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"有","pct_outstanding":0.33836057368069833,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.04625105985144278,"pct_of_holder_assets":0.03342416383605531,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"持田製薬株式会社","holder_name_en":"Mochida Pharmaceutical Co.,Ltd.","holder_sec_code":"4534","doc_id":"S100YI28","period_end":"2026-03-31","holder_table":"reporting","shares":172920,"book_value_yen":1026000000,"prior_shares":172920,"prior_book_value_yen":854000000,"purpose_ja":"取引関係の維持・強化のため、保有しております。保有効果を定量的に量りかねるため、取引関係への影響を含む現在及び将来の意義を総合的に判断のうえ、保有の適否を取締役会において、検証しました。なお、同社と医薬品販売等の重要な取引を行っております。","reciprocal":"有","pct_outstanding":0.2556554679754713,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.7311545971523452,"pct_of_holder_assets":0.5615148861646234,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":140326000000,"holder_total_assets_yen":182720000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社ツムラ","holder_name_en":"TSUMURA & CO.","holder_sec_code":"4540","doc_id":"S100YFC1","period_end":"2026-03-31","holder_table":"reporting","shares":132913,"book_value_yen":788000000,"prior_shares":132913,"prior_book_value_yen":656000000,"purpose_ja":"医薬品販売等の取引関係を維持・強化し、中長期的な企業価値の向上のため保有しており、当社の資本コストと配当金・取引額の比較等により、当社に便益があることを確認しています。","reciprocal":"有","pct_outstanding":0.19650668063280022,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.21205426220993912,"pct_of_holder_assets":0.1329360995738622,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":371603000000,"holder_total_assets_yen":592766000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"日本化薬株式会社","holder_name_en":"NIPPON KAYAKU CO.,LTD.","holder_sec_code":"4272","doc_id":"S100YD4R","period_end":"2026-03-31","holder_table":"reporting","shares":63492,"book_value_yen":376000000,"prior_shares":63492,"prior_book_value_yen":313000000,"purpose_ja":"（保有目的）ライフサイエンス事業領域における販売先として関係の維持、強化を図るため（定量的な保有効果）　（注）1","reciprocal":"有","pct_outstanding":0.093870442821528,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.1342358552537629,"pct_of_holder_assets":0.09429798162192528,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":280104000000,"holder_total_assets_yen":398736000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"杏林製薬株式会社","holder_name_en":"KYORIN Pharmaceutical Co., Ltd.","holder_sec_code":"4569","doc_id":"S100YDHG","period_end":"2026-03-31","holder_table":"reporting","shares":58731,"book_value_yen":348000000,"prior_shares":58731,"prior_book_value_yen":290000000,"purpose_ja":"医薬品の安定供給を図るため、同社の充実した販売網を経常的に活用するために保有するものであり、当社の持続成長や企業価値向上の観点から総合的に保有の適否を検証しております","reciprocal":"有","pct_outstanding":0.086831490224771,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.24433912585571355,"pct_of_holder_assets":0.17804609756721496,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":142425000000,"holder_total_assets_yen":195455000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"大正製薬ホールディングス株式会社","holder_name_en":"TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.","holder_sec_code":"4581","doc_id":"S100R80T","period_end":"2023-03-31","holder_table":"reporting","shares":98555,"book_value_yen":330000000,"prior_shares":98555,"prior_book_value_yen":357000000,"purpose_ja":"当社医薬事業における販売取引関係の維持・強化のために保有しています。","reciprocal":"有","pct_outstanding":0.11912574863501268,"pct_unavailable":null,"pct_basis_period_end":"2023-03-31","pct_share_classes":1,"pct_of_holder_equity":0.04077381283337225,"pct_of_holder_assets":0.03505082369435682,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":809343000000,"holder_total_assets_yen":941490000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"久光製薬株式会社","holder_name_en":"HISAMITSU PHARMACEUTICAL CO.,INC.","holder_sec_code":"4530","doc_id":"S100VT69","period_end":"2025-02-28","holder_table":"reporting","shares":40462,"book_value_yen":192000000,"prior_shares":40462,"prior_book_value_yen":180000000,"purpose_ja":"医薬品事業の販売先であり、取引関係維持・強化を図るため。","reciprocal":"有","pct_outstanding":0.056144817273610335,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.06871696127870812,"pct_of_holder_assets":0.055965581167581935,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"科研製薬株式会社","holder_name_en":"KAKEN PHARMACEUTICAL CO., LTD.","holder_sec_code":"4521","doc_id":"S100YK2Q","period_end":"2026-03-31","holder_table":"reporting","shares":25300,"book_value_yen":150000000,"prior_shares":25300,"prior_book_value_yen":124000000,"purpose_ja":"医薬品販売に係る取引円滑化のため、当社の持続成長や企業価値向上から総合的に判断し保有しております。","reciprocal":"有","pct_outstanding":0.037405062108370475,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.1016129360041729,"pct_of_holder_assets":0.08416705477030811,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":147619000000,"holder_total_assets_yen":178217000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"あすか製薬ホールディングス株式会社","holder_name_en":"ASKA Pharmaceutical Holdings Co., Ltd.","holder_sec_code":"4886","doc_id":"S100YEAY","period_end":"2026-03-31","holder_table":"largest","shares":21232,"book_value_yen":126000000,"prior_shares":21232,"prior_book_value_yen":104000000,"purpose_ja":"医薬品事業等における特約店であり、中長期的な取引関係の維持と強化を図るため","reciprocal":"有","pct_outstanding":0.031390682951973205,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.16402192166000598,"pct_of_holder_assets":0.1121205919255377,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"わかもと製薬株式会社","holder_name_en":"WAKAMOTO PHARMACEUTICAL CO.,LTD.","holder_sec_code":"4512","doc_id":"S100YDBU","period_end":"2026-03-31","holder_table":"reporting","shares":18579,"book_value_yen":110266000,"prior_shares":18579,"prior_book_value_yen":91780000,"purpose_ja":"医薬事業における顧客であり、取引関係の維持・強化のため保有しています。","reciprocal":"有","pct_outstanding":0.02746832604392945,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.9182267247062746,"pct_of_holder_assets":0.6682947054435903,"holder_equity_basis":"parent_only","holder_equity_yen":12008581000,"holder_total_assets_yen":16499607000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社マツキヨココカラ＆カンパニー","holder_name_en":"MatsukiyoCocokara&Co.","holder_sec_code":"3088","doc_id":"S100YD1I","period_end":"2026-03-31","holder_table":"reporting","shares":14374,"book_value_yen":85000000,"prior_shares":14374,"prior_book_value_yen":71000000,"purpose_ja":"（保有目的）商品の安定供給（商品仕入）を通じた当社事業の円滑化のため保有（定量的な保有効果）（注）２ ","reciprocal":"有","pct_outstanding":0.02125139773698487,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.015612056916049378,"pct_of_holder_assets":0.011245900207850696,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":544451000000,"holder_total_assets_yen":755831000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社ナカノフドー建設","holder_name_en":"NAKANO CORPORATION","holder_sec_code":"1827","doc_id":"S100YHMT","period_end":"2026-03-31","holder_table":"reporting","shares":11616,"book_value_yen":68000000,"prior_shares":11616,"prior_book_value_yen":57000000,"purpose_ja":"建設事業において取引実績があり、今後も取引案件が見込まれるため保有する。","reciprocal":"無","pct_outstanding":0.01717380242888662,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.13231631382316314,"pct_of_holder_assets":0.06747169661550063,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":51392000000,"holder_total_assets_yen":100783000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社ココカラファイン","holder_name_en":"cocokara fine Inc.","holder_sec_code":"3098","doc_id":"S100MCXH","period_end":"2021-03-31","holder_table":"second_largest","shares":14374,"book_value_yen":62000000,"prior_shares":14374,"prior_book_value_yen":56000000,"purpose_ja":"医薬品仕入等の取引を行っており、資本コスト等を勘案し、取引関係の維持・拡大を図るため、継続して保有しています。","reciprocal":"有","pct_outstanding":0.01611888854398609,"pct_unavailable":null,"pct_basis_period_end":"2020-03-31","pct_share_classes":1,"pct_of_holder_equity":0.04381377731294344,"pct_of_holder_assets":0.030480760249155633,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":141508000000,"holder_total_assets_yen":203407000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"トランコム株式会社","holder_name_en":"TRANCOM CO., LTD.","holder_sec_code":"9058","doc_id":"S100TN1U","period_end":"2024-03-31","holder_table":"reporting","shares":7986,"book_value_yen":37000000,"prior_shares":7986,"prior_book_value_yen":26000000,"purpose_ja":"（保有目的）取引先との円滑で長期的な関係の構築（定量的な保有効果）（注）","reciprocal":"無","pct_outstanding":0.010285832809596484,"pct_unavailable":null,"pct_basis_period_end":"2024-03-31","pct_share_classes":1,"pct_of_holder_equity":0.07364503095081706,"pct_of_holder_assets":0.04993454525824258,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":50241000000,"holder_total_assets_yen":74097000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"太洋基礎工業株式会社","holder_name_en":"Taiyo Kisokogyo Co.,Ltd.","holder_sec_code":"1758","doc_id":"S100Y01F","period_end":"2026-01-31","holder_table":"reporting","shares":4791,"book_value_yen":29838000,"prior_shares":4791,"prior_book_value_yen":23236000,"purpose_ja":"業務取引強化のため。","reciprocal":"無","pct_outstanding":0.00708330642534399,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.314155639598056,"pct_of_holder_assets":0.23976348607333975,"holder_equity_basis":"parent_only","holder_equity_yen":9497840000,"holder_total_assets_yen":12444764000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社ｍｅｉｔｏ","holder_name_en":"MEITO CO.,LTD.","holder_sec_code":"2207","doc_id":"S100YHY5","period_end":"2026-03-31","holder_table":"reporting","shares":4791,"book_value_yen":28000000,"prior_shares":4791,"prior_book_value_yen":23000000,"purpose_ja":"製品販売における取引関係の維持・強化のため。","reciprocal":"無","pct_outstanding":0.00708330642534399,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.04504214658001415,"pct_of_holder_assets":0.027910964024761013,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":62164000000,"holder_total_assets_yen":100319000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"東京センチュリー株式会社","holder_name_en":"Tokyo Century Corporation","holder_sec_code":"8439","doc_id":"S100YDRI","period_end":"2026-03-31","holder_table":"reporting","shares":4791,"book_value_yen":28000000,"prior_shares":4791,"prior_book_value_yen":23000000,"purpose_ja":"発行会社グループへのリース、各種ソリューションの提供による取引関係強化を目的として保有しております。強固な取引関係を維持することで、安定的な収益基盤の維持・向上に努めております。","reciprocal":"無","pct_outstanding":0.00708330642534399,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.002235362963069409,"pct_of_holder_assets":0.00038809060806868097,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":1252593000000,"holder_total_assets_yen":7214810000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"フマキラー株式会社","holder_name_en":"FUMAKILLA LIMITED","holder_sec_code":"4998","doc_id":"S100YGPK","period_end":"2026-03-31","holder_table":"reporting","shares":2395,"book_value_yen":14000000,"prior_shares":2395,"prior_book_value_yen":11000000,"purpose_ja":"販売取引関係の維持・発展のため（定量的な保有効果）（注）","reciprocal":"無","pct_outstanding":0.003540913982195545,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.047737579704708974,"pct_of_holder_assets":0.020421261450493028,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":29327000000,"holder_total_assets_yen":68556000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社メディパルホールディングス","holder_name_en":"MEDIPAL HOLDINGS CORPORATION","holder_sec_code":"7459","doc_id":"S100YI1C","period_end":"2026-03-31","holder_table":"reporting","shares":1000,"book_value_yen":5000000,"prior_shares":1000,"prior_book_value_yen":4000000,"purpose_ja":"・事業の円滑な取引関係維持のため保有しております。 ・定量的な保有効果については、（注）１に記載しております。","reciprocal":"無","pct_outstanding":0.0014784609529000189,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0006286153238814733,"pct_of_holder_assets":0.0002601454108788648,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"キムラユニティー株式会社","holder_name_en":"KIMURA UNITY CO.,LTD.","holder_sec_code":"9368","doc_id":"S100YCXZ","period_end":"2026-03-31","holder_table":"reporting","shares":924,"book_value_yen":5000000,"prior_shares":924,"prior_book_value_yen":4000000,"purpose_ja":"保有目的は、主要な物流サービスまたはモビリティーサービスの顧客で取引維持や拡大のためです。業務提携等は、ありません。定量的保有効果は、コーポレートガバナンスコードの基準にて、収益の増加や株式保有コストなどの経済的合理性の適否を評価し、保有するのが妥当と判断しております。","reciprocal":"無","pct_outstanding":0.0013660979204796174,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0107986696039048,"pct_of_holder_assets":0.007008592534447232,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":46302000000,"holder_total_assets_yen":71341000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"日医工株式会社","holder_name_en":"Nichi-Iko Pharmaceutical Co., Ltd.","holder_sec_code":"4541","doc_id":"S100OLZH","period_end":"2022-03-31","holder_table":"reporting","shares":1381,"book_value_yen":5000000,"prior_shares":1381,"prior_book_value_yen":5000000,"purpose_ja":"(保有目的)当社の販売先である医薬品卸であり、販売協力関係構築を目的として保有しております。","reciprocal":"有","pct_outstanding":0.0015703570622396864,"pct_unavailable":null,"pct_basis_period_end":"2022-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0373301478273854,"pct_of_holder_assets":0.0019189511780441282,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":13394000000,"holder_total_assets_yen":260559000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"エーザイ株式会社","holder_name_en":"Eisai Co., Ltd.","holder_sec_code":"4523","doc_id":"S100YB05","period_end":"2026-03-31","holder_table":"reporting","shares":100,"book_value_yen":1000000,"prior_shares":100,"prior_book_value_yen":0,"purpose_ja":"・医療用医薬品販売事業等における取引関係の強化のため保有しています。・定量的な保有効果を検証しています。","reciprocal":"有","pct_outstanding":0.0001478460952900019,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.00011123569508961148,"pct_of_holder_assets":6.900773093609678e-05,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":898992000000,"holder_total_assets_yen":1449113000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"ゼリア新薬工業株式会社","holder_name_en":"ZERIA PHARMACEUTICAL CO., LTD.","holder_sec_code":"4559","doc_id":"S100YKC2","period_end":"2026-03-31","holder_table":"reporting","shares":66,"book_value_yen":391000,"prior_shares":66,"prior_book_value_yen":326000,"purpose_ja":"（保有目的）医療用医薬品事業活動の円滑な推進（定量的な保有効果）（注）１","reciprocal":"有","pct_outstanding":9.757842289140125e-05,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.00036002095303531273,"pct_of_holder_assets":0.00021758734708763981,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":108604790000,"holder_total_assets_yen":179697949000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"東邦ホールディングス株式会社","holder_name_en":"TOHO HOLDINGS CO.,LTD.","holder_sec_code":"8129","doc_id":"S100YHSN","period_end":"2026-03-31","holder_table":"reporting","shares":100,"book_value_yen":0,"prior_shares":100,"prior_book_value_yen":0,"purpose_ja":"医薬品の仕入れ等の取引において緊密な関係を維持するため","reciprocal":"有","pct_outstanding":0.0001478460952900019,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0,"pct_of_holder_assets":0.0,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"アルフレッサホールディングス株式会社","holder_name_en":"Alfresa Holdings Corporation","holder_sec_code":"2784","doc_id":"S100YH29","period_end":"2026-03-31","holder_table":"largest","shares":100,"book_value_yen":0,"prior_shares":100,"prior_book_value_yen":0,"purpose_ja":"・同業界内における関係維持発展に伴う中　長期的な企業価値の向上・当社グループの取引先・検証実施(注)１","reciprocal":"有","pct_outstanding":0.0001478460952900019,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0,"pct_of_holder_assets":0.0,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":507903000000,"holder_total_assets_yen":1507016000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"参天製薬株式会社","holder_name_en":"SANTEN PHARMACEUTICAL CO., LTD.","holder_sec_code":"4536","doc_id":"S100YDH1","period_end":"2026-03-31","holder_table":"reporting","shares":null,"book_value_yen":null,"prior_shares":42226,"prior_book_value_yen":209000000,"purpose_ja":"当社医薬品等の販売契約があり、眼科領域における事業関係の強化を図ることを目的に保有していましたが、当事業年度において全株式を売却しました。","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":296989000000,"holder_total_assets_yen":423033000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"キッセイ薬品工業株式会社","holder_name_en":"KISSEI PHARMACEUTICAL CO., LTD.","holder_sec_code":"4547","doc_id":"S100YFN3","period_end":"2026-03-31","holder_table":"reporting","shares":null,"book_value_yen":null,"prior_shares":115860,"prior_book_value_yen":572000000,"purpose_ja":"当事業年度において全株売却したため、2026年３月末現在保有していません。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":231536000000,"holder_total_assets_yen":275086000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"扶桑薬品工業株式会社","holder_name_en":"Fuso Pharmaceutical Industries, Ltd.","holder_sec_code":"4538","doc_id":"S100YHSC","period_end":"2026-03-31","holder_table":"reporting","shares":null,"book_value_yen":null,"prior_shares":30030,"prior_book_value_yen":148000000,"purpose_ja":"－","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"parent_only","holder_equity_yen":35057000000,"holder_total_assets_yen":90323000000,"implausible":false,"reciprocal_held_both_ways":true}],"reclassified":[],"reclassified_note":"As filed, from the annual report's 保有目的を変更した投資株式 table. direction=to_pure means the filer moved the holding from a policy shareholding to 純投資目的 (pure investment); the shares are not necessarily sold, and the position leaves the named policy table in the year of the change. direction=to_policy is the reverse. fy_of_change_ja is the fiscal year the filer states the change took effect, verbatim — some filers list more than one. A filing repeats these rows for several years after the change, so this is a standing disclosure, not a one-year event.","implausible_note":"A row is flagged implausible when its two filed numbers are mutually impossible — book value ÷ shares of ¥1,000,000 or more, which no listed Japanese share reaches. It is a filer tagging error (a value entered at the wrong scale, or a share count in thousands), not an extraction error: the values match the filing's XBRL exactly. Flagged rows are still returned, exactly as filed, but are excluded from the yen aggregates here and counted in excluded_positions / excluded_yen so the exclusion is visible.","notes":[{"holder_table":"reporting","note_no":"1","text_ja":"（注）１ 定量的な保有効果の記載が困難な銘柄については、保有の合理性を検証した方法を記載しております。"},{"holder_table":"reporting","note_no":"2","text_ja":"２ 保有先企業は、当社の株式を保有しておりませんが、同社子会社が当社の株式を保有しております。"},{"holder_table":"reporting","note_no":"3","text_ja":"３ 2025年12月１日付で㈱ツルハホールディングスと株式交換しております。これに伴い、ウエルシアホールディングス㈱の普通株式１株に対して、㈱ツルハホールディングスの普通株式1.15株が割当交付されております。"}],"notes_note":"The filing's own numbered footnotes to the named policy table, verbatim. The XBRL numbers them (注)1, (注)2 … and gives no link back to a row, so a note is tied to a position only where it names that issuer.","flows":[{"holder_table":"reporting","share_class":"listed","issues_increased":5,"acquisition_cost_yen":616000000,"issues_decreased":6,"sale_proceeds_yen":14021000000,"entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":null,"sale_proceeds_yen":null,"entity_scope":"parent_only","share_scope":"unlisted"}],"flows_note":"The filer's own tally, as filed, of how many issues increased or decreased during the year and the yen involved — acquisition cost for increases, sale proceeds for decreases. Read against the reclassification table this separates what was actually sold from what merely changed category. Counts are as filed and are not corrected for filer tagging errors.","no_reduction_measure":"This product holds sale proceeds (売却価額), as filed, for one fiscal year. It does NOT hold a book-value-reduction measure. The two are different measures and must never be presented as equivalent.","scale":{"policy_total_yen":51760000000,"listed_yen":48172000000,"unlisted_yen":3588000000,"listed_issues":31,"unlisted_issues":28,"equity_yen":416012000000,"equity_basis":"jgaap_consolidated","total_assets_yen":1155766000000,"assets_basis":"jgaap_consolidated","pct_of_equity":12.441948789938753,"pct_of_assets":4.478415180927628,"equity_basis_label":"Consolidated net assets (Japanese GAAP)","assets_basis_label":"Consolidated net assets (Japanese GAAP)","equity_calc":"total policy shareholdings ÷ shareholders' equity × 100, both as filed in this annual securities report","assets_calc":"total policy shareholdings ÷ total assets × 100, both as filed in this annual securities report"},"scale_entities":[{"holder_table":"reporting","share_class":"listed","book_value_yen":48172000000,"issue_count":31,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","book_value_yen":3588000000,"issue_count":28,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"unlisted"}],"scale_history":[{"year":"2020","period_end":"2020-03-31","policy_total_yen":61785000000,"equity_yen":412708000000,"equity_basis":"jgaap_consolidated","pct_of_equity":14.970632989910541,"pct_of_assets":5.553672920709713},{"year":"2022","period_end":"2022-03-31","policy_total_yen":58517000000,"equity_yen":418062000000,"equity_basis":"jgaap_consolidated","pct_of_equity":13.997206156024705,"pct_of_assets":5.12535067797011},{"year":"2023","period_end":"2023-03-31","policy_total_yen":60831000000,"equity_yen":411525000000,"equity_basis":"jgaap_consolidated","pct_of_equity":14.781848004373975,"pct_of_assets":5.307665930545146},{"year":"2024","period_end":"2024-03-31","policy_total_yen":62529000000,"equity_yen":416428000000,"equity_basis":"jgaap_consolidated","pct_of_equity":15.015560913291132,"pct_of_assets":5.089095179728588},{"year":"2025","period_end":"2025-03-31","policy_total_yen":51313000000,"equity_yen":407420000000,"equity_basis":"jgaap_consolidated","pct_of_equity":12.594619802660645,"pct_of_assets":4.606892787146345},{"year":"2026","period_end":"2026-03-31","policy_total_yen":51760000000,"equity_yen":416012000000,"equity_basis":"jgaap_consolidated","pct_of_equity":12.441948789938753,"pct_of_assets":4.478415180927628}],"scale_note":"The policy total is Official (as filed) — the filing's own total carrying amount for the whole policy bucket, listed and unlisted, summed across the entities the filing discloses. It is a floor: holdings at group companies the filing does not name are disclosed nowhere and are not included. The percentages are calculated, not filed, and carry their formula. equity_basis names which figure the denominator is, because filers report under Japanese, IFRS or US accounting standards and an adopter of the latter two stops tagging the Japanese consolidated figure — a parent-only denominator is a different measure and is labelled as one, never silently mixed with a group figure. Percentages are null where equity or total assets is missing or not positive; missing is never shown as zero.","scale_reference":"ISS's Japan proxy voting guidelines recommend a vote against the top executive at a company that allocates 20 percent or more of its net assets to cross-shareholdings, a policy effective from February 2022. ISS counts unilateral holdings, not only mutual ones.","ownership_calc":"shares held ÷ (issuer's issued shares − treasury shares) × 100, both as filed, the denominator taken from the issuer's own annual securities report nearest the holding's fiscal year end","ownership_note":"Derived, not filed. The denominator is the issuer's own reported issued shares less treasury shares, from its annual report nearest this holding's fiscal year end on either side — pct_basis_period_end gives that date, and it can fall after the holding's date where that report is the closer one. For a single-class listed stock this equals the stake's share of market capitalisation. It is null where the issuer files no annual report we hold; where the issuer's share count moves by half or more across the window, because a split or issue makes the share base indeterminate; and where the result would exceed 100%, which is a data fault rather than a stake. It is less exact where the issuer has more than one share class (pct_share_classes > 1), because treasury shares are reported across all classes.","holder_share_calc":"this position's book value ÷ the holder's shareholders' equity (or total assets) × 100, both as filed in the holder's own annual securities report","holder_share_note":"The mirror of pct_outstanding. That sizes a stake against the ISSUER — how much of the issuer this holder owns. pct_of_holder_equity and pct_of_holder_assets size the same position against the HOLDER: how much of its own capital is committed to this one name. Calculated, not filed. Null where the holder's filing gives no usable denominator, never zero. holder_equity_basis says which accounting figure the denominator is, and a parent_only basis is not comparable with a consolidated one. A position CAN legitimately exceed 100% of equity — a holder whose book equity is smaller than one long-held stake is a real and commercially interesting case, not an error — so no ceiling is imposed. Extreme values are worth checking against the filing: where the position's own two filed numbers are mutually impossible the row is marked `implausible`, but that test catches only scale errors visible per share, so it does not catch every bad figure. The book value and share count are returned alongside so the reader can check.","action_calc":"keyword match over the filing's own stated purpose and table footnotes: 株式分割、株式併合、株式交換、株式移転、会社分割、合併、持株会社、商号変更、公開買付、上場廃止","ratio_calc":"current shares ÷ prior shares where that ratio is an exact whole number (or its exact reciprocal) — the signature of a split or a consolidation rather than a trade","history":[{"year":"2019","period_end":"2019-03-31","named_holdings":53,"book_value_yen":60900000000},{"year":"2020","period_end":"2020-03-31","named_holdings":54,"book_value_yen":60390000000},{"year":"2022","period_end":"2022-03-31","named_holdings":52,"book_value_yen":54537000000},{"year":"2023","period_end":"2023-03-31","named_holdings":49,"book_value_yen":53355000000},{"year":"2024","period_end":"2024-03-31","named_holdings":45,"book_value_yen":58226000000},{"year":"2025","period_end":"2025-03-31","named_holdings":39,"book_value_yen":47701000000},{"year":"2026","period_end":"2026-03-31","named_holdings":37,"book_value_yen":48158000000}],"history_note":"One point per annual report filed. Each year's book value is as filed; book values are fair-valued at period end, so a change reflects both trading and market moves.","provenance":{"trust":"official","note":"Figures exactly as filed in each company's 有価証券報告書 (annual securities report), EDINET. Raw filings archived with SHA-256; doc_id links to the source filing."}}